While further studies are warranted to address these issues and optimize delivery—potentially using lipid nanoparticles, aptamer conjugation, or viral vectors—the current findings provide a compelling proof of concept for DNAzyme-based cancer therapeutics, particularly for genes like BCL-2, where dysregulation plays a central role in tumor survival and chemoresistance [46]. The gene discussed is BCL2; the disease is cancer.